The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force to critically review the evidence for iron chelation and the rationale for treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS). The task force was charged with addressing issues related to tissue iron toxicity; the role of MRI in assessing iron overload; the rationale and role of treating transfusional iron overload in patients with MDS; and the impact of iron overload on bone marrow transplantation. This report summarizes the background data and ensuing discussion from the NCCN Task Force meeting on transfusional iron overload in MDS.
If the inline PDF is not rendering correctly, you can download the PDF file here.
DeleaTEHagiwaraMPhatakPD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin2009;25:139–147.
TakatokuMUchiyamaTOkamotoS. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol2007;78:487–494.
PlatzbeckerUBornhauserMGermingU. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant2008;14:1217–1225.
MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:7594–7603.
CappelliniMDBejaouiMAgaogluL. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther2007;29:909–917.
CappelliniMDEl-BeshlawyAKattamisA. Efficacy and safety of deferasirox (Exjade(R)) in patients with transfusion-dependent anemias: 1-year results from the large, prospective, multicenter EPIC study [abstract]. Blood2008;112:Abstract 3875.
PorterJBCappelliniMDEl-BeshlawyA. Effect of deferasirox (Exjade(R)) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-Year EPIC trial [abstract]. Blood2008;112:Abstract 3881.
GattermannNSchmidMPortaMD. Efficacy and safety of deferasirox (Exjade(R)) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial [abstract]. Blood2008;112:Abstract 633.
De WitteTZwaanFHermansJ. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol1990;74:151–155.
AlessandrinoEPDella PortaMGBacigalupoA. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica2009; in press.